Key facts
- This page summarizes Ansbert Gadicke's Form 4 filing for Aktis Oncology, Inc. (AKTS).
- 7 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 14 Jan 2026, 18:17.
Ansbert Gadicke - 12 Jan 2026 Form 4 Insider Report for Aktis Oncology, Inc. (AKTS)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- AKTS
- Reported as of
- 12 Jan 2026
- Net transaction value
- +$20,029,986
- SEC form
- 4
- Accepted by SEC
- 14 Jan 2026, 18:17:54 UTC
- Prior SEC filing
- 08 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ansbert Gadicke
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ansbert Gadicke filed Form 4 for Aktis Oncology, Inc. (AKTS) on 14 Jan 2026.
Change
- Previous filing in this sequence was filed on 08 Jan 2026.
- Current net transaction value: +$20,029,986.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (3)
CIK 0001134655
Primary reporting owner
GADICKE ANSBERT
- Relationship
- 10%+ Owner
- Address
- C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON
- Signature
- /s/ Ansbert Gadicke
- Signature date
- 14 Jan 2026
CIK 0001263048
MPM ASSET MANAGEMENT LLC
- Relationship
- 10%+ Owner
- Address
- C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON
- Signature
- /s/ Ansbert Gadicke, manager of MPM Asset Management LLC
- Signature date
- 14 Jan 2026
CIK 0002104306
Oncology Impact Private Investment Fund 2, L.P.
- Relationship
- 10%+ Owner
- Address
- C/O MPM BIOIMPACT LLC, 399 BOYLSTON STREET, SUITE 1100, BOSTON
- Signature
- /s/ Ansbert Gadicke, managing member of MPM Oncology Investments 2 LLC
- Signature date
- 14 Jan 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKTS
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +1,314,262
- Change %
- +385%
- Price
- Shares after
- 1,655,971
- Date
- 12 Jan 2026
- Ownership
- See Footnote
- Footnotes
- F1, F2, F3, F4
AKTS
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +5,914,197
- Change %
- +357%
- Price
- Shares after
- 7,570,168
- Date
- 12 Jan 2026
- Ownership
- See Footnote
- Footnotes
- F2, F3, F5, F6
AKTS
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +1,577,119
- Change %
- +21%
- Price
- Shares after
- 9,147,287
- Date
- 12 Jan 2026
- Ownership
- See Footnote
- Footnotes
- F2, F3, F7, F8
AKTS
transaction
Common Stock
Purchase
- Transaction value
- $20,029,986
- Shares
- +1,112,777
- Change %
- +12%
- Price
- $18.00
- Shares after
- 10,260,064
- Date
- 12 Jan 2026
- Ownership
- See Footnote
- Footnotes
- F3, F9, F10
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AKTS
transaction
Derivative
Series Seed Redeemable Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -5,000,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 12 Jan 2026
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 1,314,262
- Exercise price
- Footnotes
- F1, F2, F3
AKTS
transaction
Derivative
Series A Redeemable Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -22,500,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 12 Jan 2026
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 5,914,197
- Exercise price
- Footnotes
- F2, F3, F5
AKTS
transaction
Derivative
Series B Redeemable Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -6,000,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 12 Jan 2026
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 1,577,119
- Exercise price
- Footnotes
- F2, F3, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 10 footnotes
Footnote F1
The shares of common stock were issued upon conversion as follows: 556,810 by MPM BioVentures 2018, L.P. ("BV 2018"), 29,593 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)"), 10,988 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"), 119,478 by MPM Oncology Innovations Fund, L.P. ("MPM Oncology") and 597,393 by Oncology Impact Private Investment Fund 2, L.P. ("MPM Oncology Impact"). MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Drs. Evnin and Gadicke are managing directors of BV 2018 LLC and managers of MPM Oncology Innovations Fund GP LLC, which is the general partner of MPM Oncology. Dr. Gadicke is the managing member of MPM Oncology Investments 2 LLC, which is the general partner of MPM Oncology Impact.
Footnote F2
Each share of Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.8044-for-1 basis into the number of shares of Common Stock shown in Column 7 without payment of further consideration upon the closing of the initial public offering of the Issuer's Common Stock. The Series Seed Redeemable Convertible Preferred Stock, Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date.
Footnote F3
The Reporting Persons disclaim beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Footnote F4
The shares are held as follows: 341,709 by MPM Asset Management LLC ("MPM AM"), 556,810 by BV 2018, 29,593 by BV 2018(B), 10,988 by AM BV2018, 119,478 by MPM Oncology and 597,393 by MPM Oncology Impact. Dr. Gadicke is the manager of MPM AM.
Footnote F5
The shares of common stock were issued upon conversion as follows: 2,505,648 by BV 2018, 133,170 by BV 2018(B), 49,452 by AM BV2018, 537,654 by MPM Oncology and 2,688,273 by MPM Oncology Impact.
Footnote F6
The shares are held as follows: 341,709 by MPM AM, 3,062,458 by BV 2018, 162,763 by BV 2018(B), 60,440 by AM BV2018, 657,132 by MPM Oncology and 3,285,666 by MPM Oncology Impact.
Footnote F7
The shares of common stock were issued upon conversion as follows: 668,173 by BV 2018, 35,512 by BV 2018(B), 13,187 by AM BV2018, 143,374 by MPM Oncology and 716,873 by MPM Oncology Impact.
Footnote F8
The shares are held as follows: 341,709 by MPM AM, 3,730,631 by BV 2018, 198,275 by BV 2018(B), 73,627 by AM BV2018, 800,506 by MPM Oncology and 4,002,539 by MPM Oncology Impact.
Footnote F9
The shares were purchased as follows: 219,897 by BV 2018, 8,689 by BV 2018(B), 4,284 by AM BV2018, 46,574 by MPM Oncology and 833,333 by MPM Oncology Impact.
Footnote F10
The shares are held as follows: 341,709 by MPM AM, 3,950,528 by BV 2018, 206,964 by BV 2018(B), 77,911 by AM BV2018, 847,080 by MPM Oncology and 4,835,872 by MPM Oncology Impact.
SEC remarks
This filing is 1 of 2 identical filings due to limitations on number of Reporting Persons. See Form 4 filed by MPM BioVentures 2018, L.P.